Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)
about
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.DNA methylation and cancer.Comment on "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity"Epigenetic targets for immune intervention in human malignancies.Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implicationsCancer/testis antigens and urological malignanciesCancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsEpigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesStrategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cellsCancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialAntigens in chronic myeloid leukemia: implications for vaccine development.Epigenetics of melanoma: implications for immune-based therapies.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression.No patient left behind: The promise of immune priming with epigenetic agents.The emerging role of immune checkpoint based approaches in AML and MDS.Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.Epigenetically regulated tumor-associated antigens in melanoma
P2860
Q33416734-200248C9-310A-4ABB-AFEA-7D2B5958AA88Q33784789-E1283BB8-1E6E-4B01-8F68-CD4EF441F676Q33875819-88BB4103-B71D-4467-B2DA-D75D5BC98384Q35207569-6D45FEA5-6490-449D-ABBB-2676B2498AEEQ35551107-68113AA8-0EF0-43A5-AA5C-84A58B59121EQ35589288-F051CBE4-3B55-40E9-B91B-3931C25AB4A5Q36060324-1ACEB989-EE1F-4AAD-8A25-7B7A27856288Q36067682-01B2EFA5-DB93-46F1-9781-640D1C18B029Q36136992-DCF63916-B633-4E17-B820-E3FCC371A0FAQ36287972-5619158D-07BD-4354-B319-17B4900C0F83Q36337004-EB248341-AB0A-4583-A608-014DC0D58FA6Q36623761-AB70B0EA-4C1A-4F4C-865E-8097ED81B18DQ36801625-EBFD33B6-4DB2-433A-A20D-BE7A5C81987DQ36831746-C77B4BB0-C252-44F2-8AA2-251814D5CA71Q37000485-50F5FE7F-267E-4D43-BB08-23A627D423B9Q37285301-CF95D12D-D07C-4873-8E22-9F7E0E77FCDCQ37737327-70783572-FF5C-41B2-9F51-75A695967256Q37849976-4E346371-EF67-4A06-B30C-1A8B33883C90Q37950233-ABDF68AF-2A01-4D6B-BAF2-5DBA8A3ECDCBQ38148588-61CFBA9D-5D2A-4DD4-99A9-38897A734359Q38197075-34000E8F-7168-4444-8576-565F7D62BC09Q38314204-FCC9436D-CD2D-4962-B0D3-69D43B5E1F0FQ38390185-D3E9F52C-BCAB-406B-B461-EB23D5DE4DC8Q38588894-85F403CF-2FFC-4FA7-9FD8-730B22CA9C0FQ39019419-AF6FA0BF-F093-4E8D-A848-8B58BD225B89Q39247530-E7912451-9495-4D73-8E6A-72381B09D171Q39500230-76FF4FB9-4EBD-4BFC-A209-B3497A7A91FFQ40819482-B74A0C6E-B5EE-4519-8215-E8BEA6C6C92DQ46665179-21C2F0E9-75E0-46DF-B850-13F0C1674A26Q48173100-675D48CA-26F0-472C-929E-C056CC7492A7Q53528762-D0A0BCAF-58D8-420D-B695-5B90F49539A3Q53981715-759699C5-7CF6-48E8-AC2E-7B0F1928E3DFQ57570339-B500A319-6295-4F77-8544-427D3908DAD3
P2860
Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)
description
scientific article published on 01 January 1999
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1999
@uk
name
Prolonged Upregulation of the ...... -2??-deoxycytidine (5-AZA-CdR)
@en
Prolonged Upregulation of the ...... d with 5-aza-2??-deoxycytidine
@nl
type
label
Prolonged Upregulation of the ...... -2??-deoxycytidine (5-AZA-CdR)
@en
Prolonged Upregulation of the ...... d with 5-aza-2??-deoxycytidine
@nl
prefLabel
Prolonged Upregulation of the ...... -2??-deoxycytidine (5-AZA-CdR)
@en
Prolonged Upregulation of the ...... d with 5-aza-2??-deoxycytidine
@nl
P2093
P1476
Prolonged upregulation of the ...... a-2'-deoxycytidine (5-AZA-CdR)
@en
P2093
A Cattelan
A Gasparollo
A Visintin
I Cattarossi
L Sigalotti
M Altomonte
P356
10.1097/00002371-199901000-00003
P577
1999-01-01T00:00:00Z